The patent for Kerendia (finerenone) is set to expire in December 2034 [1]. This expiration date pertains to the compound patent for finerenone [1].
When can generic versions of Kerendia become available?
Generic versions of Kerendia are expected to become available after the expiration of its compound patent in December 2034 [1]. However, the actual market entry of generics can be influenced by other factors, including additional patents, exclusivity periods, and any ongoing legal challenges [2].
What is Kerendia used to treat?
Kerendia is a non-steroidal mineralocorticoid receptor antagonist used to treat adults with chronic kidney disease (CKD) associated with type 2 diabetes [3]. It works by reducing inflammation and fibrosis in the kidneys [3].
Are there other patents protecting Kerendia?
Beyond the compound patent set to expire in December 2034, other patents may cover aspects of Kerendia's formulation, manufacturing processes, or specific uses [2]. These additional patents could potentially extend market protection beyond the compound patent's expiration [2]. Information on specific patent durations can be found on DrugPatentWatch.com [1].
What is the main difference between Kerendia and older treatments for diabetic kidney disease?
Kerendia is a novel treatment that targets the underlying mechanisms of kidney damage in diabetic kidney disease by blocking the mineralocorticoid receptor [3]. Older treatments often focused on managing blood sugar and blood pressure, which are important but do not address the specific inflammatory and fibrotic pathways that Kerendia targets [3].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [3].
What clinical data supports Kerendia's use?
Clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies, demonstrated that Kerendia significantly reduced the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD [3].
What are the potential risks or side effects associated with Kerendia?
Common side effects of Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [3]. Regular monitoring of potassium levels is often recommended during treatment [3].
How does Kerendia compare to other medications for diabetic kidney disease?
While other medications manage blood sugar and blood pressure, Kerendia offers a distinct mechanism of action by targeting mineralocorticoid receptors to reduce inflammation and fibrosis in the kidneys [3]. Its specific benefit lies in addressing these underlying pathological processes contributing to kidney damage [3].
What is the projected impact of Kerendia patent expiration on drug pricing?
The expiration of Kerendia's patent is expected to pave the way for generic competition, which typically leads to lower drug prices [2]. The exact price reduction will depend on the number of generic manufacturers entering the market and market dynamics [2].
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] Bayer